THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, October 19, 2022
The North America 3D cell culture market accounted for a major share of the global market registering an estimated CAGR of 16.3 per cent during the forecast period.
FREMONT, CA:The 3D Cell Culture Market had a value of USD 1.6 billion in 2021 and is anticipated to increase at a CAGR of 18.2 per cent by 2031 to reach USD 8.3 billion. The market size, new and existing trends, projections for the future, and major players are all thoroughly examined in the report. The assembling of biological cells in an environment miming in vivo circumstances in the human body is known as 3D cell culture. Standard cultures, organ-on-chip models, and tissue bioengineering are the three basic categories under which 3D cell cultures are categorised.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The market is divided into biotechnology and pharmaceutical firms, contract research organisations, and academic institutions, according to end users. The category of academic institutes, which dominated the 3D cell culture market analysis in 2021, is anticipated to expand at an impressive rate of 18.45 per cent between 2022 and 2031.
The market has been examined regionally across four areas: North America, Europe, Asia-Pacific, and LAMEA. With a projected CAGR of 16.3 per cent throughout the projection period, the North American 3D cell culture market held a significant portion of the global market.
The 3D cell culture market is segmented into regenerative medicine, drug development, cancer research, and stem cell research. Cancer research is predicted to grow at a CAGR of 17.3 per cent from 2022 to 2031, dominating the worldwide 3D cell culture market trends in 2021.
In the following report, the global 3D cell culture market is now valued at USD 1.15 billion and is expected to grow at a 9.8 per cent CAGR during the forecast period to reach USD 2.67 billion by 2031.
However, a positive BPS growth is anticipated in H1-2022 over H1- 2021 duration with 02 Basis Point Share, according to Future Market Insights' global 3D cell culture market analysis. The H1-2022 outlook will show a negative BPS growth as opposed to the H1-2022 projected timeframe by 10 BPS (BPS).
Due to the 3D cell culture's disadvantage over surface 2D cultures during the mass transfer procedure, the market sees a decline in BPS values, making it a time-consuming and expensive factor for producers. In contrast, a rise of 02 points in the BPS value indicates a favourable market outlook. The adoption of novel cell culture devices for more predictive 3D models, which encourages cost reduction and constricts production schedules, is linked to increased BPS values. According to regulatory requirements and drug development, as well as industry- and macro-based dynamics, the market is prone to change. The inclusion of scaffold-free 3D systems for stem cell-derived therapeutics is significant market development.
More in News